30 results about "Ocular tension" patented technology

2-(6-Cyano-1-hexyn-1-yl)adenosine, 2-(6-cyano-1-hexyn-1-yl)adenosine 5′-monophosphate, or salts thereof; and drugs containing the same as an active ingredient. The compounds have excellent effects of lowering ocular tension, promoting blood flow in retina, and protecting optic nerve failure and are highly soluble in water. Owing to these characteristics, the compounds are useful as drugs such as remedies for glaucoma and ocular hypertension.

Because vision loss in most forms of glaucoma is related to elevated IOP, most glaucoma treatment protocols are concerned with lowering IOP by increasing aqueous humor outflow. The invention utilizes electromagnetic radiation to create retraction in the iris tissue, thereby (a) reducing convexity and enlarging the drainage angle and thus the area of the anterior chamber, (b) reducing contact between the zonule fibers and the iris pigment epithelium, (c) applying greater tension to both the TM and uveoscleral outflow pathways, thereby enlarging those pathways and increasing outflow.

The invention relates to a Schlemm tube expansion bracket and a combined body of the Schlemm tube expansion bracket. The expansion bracket is a hollow cylindrical shell; the cylindrical surface is formed by a continuous round curve loop bent and folded from an alloy wire; the surface of the alloy wire is coated with a coating of 10-50 microns, and the coating comprises an adhesive bottom layer and a drug layer. The tube expansion bracket disclosed by the invention can reduce the damage to the wall of a Schlemm tube, reduces restenosis and multiplication occurrence rate of a cavity of the Schlemm tube, and has good soft performance. The Schlemm tube expansion bracket disclosed by the invention can effectively and lastingly release the drug on a narrow lesion site, and guarantees local precise drug delivery of a target lesion point while reducing a serious damage on the wall of the Schlemm tube caused by the bracket wall, and therefore, the restenosis occurrence rate of the Schlemm tube can be effectively reduced, thereby achieving the purposes of promoting aqueous humour discharge, reducing intraocular tension and treating glaucoma.

The invention discloses a compound and a pharmaceutical composition and a preparation method and use thereof, the use is the use of the compound in preparation of intraocular tension reducing drugs, and the compound has very obvious intraocular tension reducing effects.

The invention discloses a compound and a pharmaceutical composition and preparation method and use thereof, the use is the use of the compound in preparation of intraocular tension reducing drugs, and the compound has very obvious intraocular tension reducing effects.

It is intended to provide a method of relieving or avoiding a steroid-induced increase in ocular tension which is caused by the administration of a steroid compound. Namely, a steroid-induced increase in ocular tension can be relieved or avoided by enclosing a steroid compound in fine particles.

The invention relates to the use of substituted cyclopentanes or cyclopentanones as ocular hypotensives. New Compounds are also provided.

The purpose of the present invention is to discover a pharmaceutical preparation which is for treating or preventing glaucoma or intraocular hypertension and exhibits effects on a patient in which theefficacy of a therapeutic agent for glaucoma or intraocular hypertension is insufficient. It is found that omidenepag, an ester thereof, or a salt thereof is proven to exhibit an excellent intraocular tension depressive action on a patient in which the efficacies of other therapeutic agents for glaucoma or intraocular hypertension are insufficient. Therefore, omidenepag, an ester thereof, or a salt thereof according to the present invention is useful as a pharmaceutical preparation capable of treating or preventing glaucoma or intraocular hypertension even on a patient in which the efficaciesof other therapeutic agents for glaucoma or intraocular hypertension are insufficient.

The invention discloses an intraocular tension reducing compound, a pharmaceutically acceptable salt and an analogue thereof, a pharmaceutical composition prepared from the intraocular tension reducing compound, the pharmaceutically acceptable salt and the analogue, and use of the intraocular tension reducing compound, the pharmaceutically acceptable salt and the analogue in preparation of intraocular tension reducing drugs, the invention discloses a preparation method and use of the intraocular tension reducing compound and the pharmaceutical composition, the intraocular tension reducing animal experiment of the intraocular tension reducing compound is performed, and the compound has very obvious intraocular tension reducing effects.

A post-positioned stress-type glaucoma drainage valve, relating to a method and device for ophthalmic surgery, in particular to a post-positioned glaucoma drainage implantation device for controlling intraocular pressure, comprising a hollow drainage tube and a valve for controlling the opening of the drainage tube. The valve cover is closed, and the outlet end of the drainage pipe is provided with an openable cover, which is composed of a drainage plate and a cover cover. The outlet end of the drainage pipe is embedded in the drainage plate, and the inlet end of the drainage pipe is perpendicular to the drainage plate. The lower surface of the lower surface protrudes downward from the lower surface of the drainage plate, and the drainage pipeline can be entered by a 23G or 25G puncture knife at the pars plana of the ciliary body; a spring pressure device is provided on the inner side of the cover and the position corresponding to the valve cover; When the cover is closed, the spring pressure device exerts pressure on the valve cover, and the spring pressure device is used to control the intraocular pressure within the normal and safe target intraocular pressure range. The inner diameter of the drainage tube is large, the length is short, and it is not easy to block , which is conducive to ensuring the safety and effectiveness of the drainage valve and realizing long-term control of intraocular pressure.

The invention discloses an intraocular tension reducing compound, a pharmaceutically acceptable salt and an analogue thereof, a pharmaceutical composition prepared from the intraocular tension reducing compound, the pharmaceutically acceptable salt and the analogue, and use of the intraocular tension reducing compound, the pharmaceutically acceptable salt and the analogue in preparation of intraocular tension reducing drugs, the invention discloses a preparation method and use of the intraocular tension reducing compound and the pharmaceutical composition, the intraocular tension reducing animal experiment of the intraocular tension reducing compound is performed, and the compound has very obvious intraocular tension reducing effects.

Provided is a novel therapeutic agent for glaucoma, which has sGC-activating action. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b) and having a Log D value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. [In formulae (I-a) and (I-b), each symbol is as defined in the description.]

The invention provides a medicinal composition with the function of protecting optic nerve, which is a preparation prepared by the following raw materials in part by weight: 40 to 400 parts of medlar and 45 to 480 parts of erigeron breviscapus. The medicament is used for treating optic neuropathy caused by liver and kidney deficiency and optic collateral stasis. The research shows that the medicinal composition has the function of protecting optic nerve. The invention is the optic nerve protection medicament for treating retinal diseases mainly comprising normal tension glaucoma, retinal vascular occlusion, diabetic retinopathy, ischemic optic neuropathy, macular degeneration, retinitis pigmentosa and Leber's disease.

RNA interference is provided for inhibition of gremlin in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.